Examination of Trump's pick to lead FDA, Marty Makary, illuminates a complex record of both support for science and embrace of RFK Jr's pseudo-science.
关于我们
BioCentury?gives?biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to?BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com
- 网站
-
https://www.biocentury.com
BioCentury Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Redwood City，CA
- 类型
- 私人持股
- 领域
- Biotechnology、Pharmaceutical、Healthcare Ecosystem、Drug Development、Business Strategy、Policy、Regulatory、Finance、Deal Making、Venture Capital和biopharma
地点
-
主要
获取路线
US，CA，Redwood City，94065
BioCentury Inc.员工
动态
-
With two more gene therapies heading to Phase III for DMD, and a preclinical program getting acquired by a pharma, Elevidys' availability does not appear to be slowing gene therapy innovation in the indication.
Elevidys isn’t slowing innovation in DMD gene therapy
biocentury.com
-
As the biopharma industry braces for Trump 2.0, leaders are facing a pivotal choices as they seek to seize new opportunities while mitigating serious threats. From potential FDA reforms to navigating the tension around controversial nominees like RFK Jr., the next administration will reshape the biomedical innovation landscape. As Washington contemplates policy changes — including reform of the IRA’s Medicare drug price negotiations, the Biosecure Act, and antitrust enforcement policies—the need for careful strategy is more urgent than ever. What will this mean for the future of the biopharma industry? BioCentury has provided a roadmap to the threats and opportunities that will define the future of biomedicine. ?
Trump 2.0 presents opportunities, threats
biocentury.com
-
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.dhirubhai.net
-
Starting in 2 hours: Join us today for BioCentury's Live Webinar. ? Learn how to stay on top of the competitive landscape by uncovering new high-potential biological?targets, compounds, and breakthrough technologies that drive therapeutic innovation.
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.dhirubhai.net
-
BioCentury Inc. is hosting Drug Development Disco. Make sure to attend tomorrow and dance like no one is watching.
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.dhirubhai.net
-
Biopharmas and academic groups are getting creative with multi-targeted CAR Ts at #ASH24 and #SITC24. New designs go beyond binding two tumor antigens.
Companies get creative with multi-targeted CARs at SITC, ASH
biocentury.com
-
Join us TOMORROW for BioCentury's Live Webinar. Reserve your spot ahead of time? Tune in this week to learn how to stay on top of the competitive landscape by uncovering new high-potential biological?targets, compounds, and breakthrough technologies that drive therapeutic innovation.
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.dhirubhai.net
-
Biotechs now match pharma for FDA approvals: Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves. Curious about how these changes are shaping the market and what it means for the future of drug approvals? Click the link below to read more about this pivotal moment in biotech history and the companies leading the charge! A BioCentury Deep Dive by Editor in Chief Simone Fishburn.
Biotechs now match pharma for FDA approvals
biocentury.com
-
Two days until BioCentury's Live Webinar, Investing in Tomorrow: The Art of Early Discovery. Reserve your spot?
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.dhirubhai.net